Overview

The Lung Cancer 105 gene panel is built for newly diagnosed non-small cell lung cancer patients who need a comprehensive genomic profile before first-line therapy. This article focuses on the patient populations that benefit most from broad next-generation sequencing at diagnosis, supplied through GIVE LIFE TIME International for reference laboratories. Ordering the broad panel up front avoids the delay of repeated single-gene tests.

How It Works

Tumor-derived DNA and RNA undergo library preparation and next-generation sequencing across 105 genes linked to lung oncogenesis. A bioinformatics pipeline reports single nucleotide variants, insertions and deletions, fusions, and copy number alterations with an actionable interpretation layer. Report reviewers prioritize alterations that match an approved or trial-based targeted agent.

Indications

It is indicated for stage III to IV adenocarcinoma, squamous carcinoma, and mixed histology where driver alteration screening guides targeted agent selection. Never-smokers and patients with limited tissue gain the most from a single broad panel instead of multiple sequential tests. It is also useful when a rapid targeted decision will shape the first line of therapy.

Specimen & Processing

Formalin-fixed paraffin-embedded tissue or a dedicated core is preferred, with a minimum of 10 to 20 unstained sections or 20 to 50 nanograms of extracted nucleic acid. Plasma-derived circulating tumor DNA is accepted when tissue is scarce. Each sample is accessioned and quality-checked before library construction. Sample identity is confirmed at every handoff, and residual material from the population-focused workflow is retained for optional confirmatory re-analysis.

Storage & Sourcing

Reports are delivered as a secure PDF through the client portal within seven to ten working days, with raw sequence data available on request. GIVE LIFE TIME International supports distributors with batch pricing, white-label options, and cold-chain sample logistics across regions. Client portals return multi-language reports for the Lung program and support bulk export to hospital information systems.

FAQ

Q: Which patients should receive the 105 gene panel first? A: Newly diagnosed advanced NSCLC, never-smokers, and anyone with scarce tissue are prioritized so one assay can surface every actionable driver at once. Early broad testing prevents wasted weeks on single-gene rounds.

Q: How much tissue is required for the lung panel? A: A core needle biopsy or 10 to 20 unstained sections are usually sufficient, and plasma circulating tumor DNA is accepted when tissue is unavailable. The laboratory confirms adequacy before sequencing begins.

Q: Does the panel report PD-L1 status alongside mutations? A: PD-L1 is assessed separately by immunohistochemistry, while this NGS report covers the genomic drivers that direct targeted therapy. Both results are reconciled by the treating team.

Q: How are results delivered to the referring clinician? A: A secure PDF summary and the underlying VCF are released through the portal, with an accompanying interpretation note for the prescriber. Urgent cases can be flagged for faster turnaround.